24.81
+0.4(+1.64%)
Currency In USD
| Previous Close | 24.41 |
| Open | 24.7 |
| Day High | 25.58 |
| Day Low | 24.18 |
| 52-Week High | 59.91 |
| 52-Week Low | 23.77 |
| Volume | 1.75M |
| Average Volume | 1.67M |
| Market Cap | 3.11B |
| PE | -15.51 |
| EPS | -1.6 |
| Moving Average 50 Days | 28.01 |
| Moving Average 200 Days | 32.86 |
| Change | 0.4 |
If you invested $1000 in Apellis Pharmaceuticals, Inc. (APLS) since IPO date, it would be worth $1,768.35 as of March 20, 2025 at a share price of $24.81. Whereas If you bought $1000 worth of Apellis Pharmaceuticals, Inc. (APLS) shares 5 years ago, it would be worth $1,016.39 as of March 20, 2025 at a share price of $24.81.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference
GlobeNewswire Inc.
Feb 24, 2025 12:00 PM GMT
WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 10:30 a.m. ET. The live con
Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN
GlobeNewswire Inc.
Feb 20, 2025 7:00 AM GMT
WALTHAM, Mass. and STOCKHOLM, Sweden, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspa
Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire Inc.
Feb 14, 2025 12:00 PM GMT
WALTHAM, Mass., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its fourth quarter and full year 2024 financial results on Friday, Fe